<\/p>\n
Assurans 20 mg<\/strong> bevat sildenafilcitraat<\/strong> as an oral tablet from Cipla. At this dose and dosing schedule, Assurans is FDA-approved for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1)<\/strong> — a serious progressive vascular disease of the lung arteries. Internationally equivalent to Revatio<\/strong> (Pfizer), the branded PAH formulation of sildenafil. Dose: 20 mg orally THREE TIMES DAILY (every 6-8 hours)<\/strong> — this is NOT the on-demand erectile-dysfunction regimen. Lowers pulmonary arterial pressure, improves exercise capacity (6-minute walk distance), and reduces WHO functional class. Specialist (pulmonary hypertension clinic) decision only<\/strong> — PAH is a rare, progressive disease that requires dedicated expert management. Absolute contraindications:<\/strong> nitrates in any form, riociguat (another PAH drug). Common side effects: headache, flushing, epistaxis (nosebleed), diarrhoea, back\/limb pain. At 20 mg three times daily, Assurans is NOT prescribed for erectile dysfunction<\/strong> — ED sildenafil uses higher on-demand doses (50-100 mg) given once before activity.<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n Assurans 20 mg is an oral sildenafil citrate 20 mg<\/strong> tablet van Cipla<\/strong>, supplied in packs of 30 \/ 60 \/ 90 \/ 180 tablets. Assurans is Cipla’s sildenafil citrate 20 mg oral tablet licensed for pulmonary arterial hypertension (PAH). From a manufacturer whose respiratory and cardiovascular medicines are used by the WHO and international pulmonary-care programmes, Assurans is the Cipla equivalent of Pfizer’s Revatio<\/strong>. The 20 mg strength is the specific formulation licensed for pulmonary arterial hypertension (PAH) — distinct from the 25 \/ 50 \/ 100 mg on-demand formulations licensed for male erectile dysfunction.<\/p>\n Sildenafil was originally developed in the 1980s as a pulmonary vasodilator candidate; its erectile-function side effects were observed in early hypertension trials and led to its 1998 FDA approval as Viagra for ED. The pulmonary hypertension development continued in parallel and sildenafil was separately FDA-approved for PAH in 2005 under the brand name Revatio<\/strong> (Pfizer). Assurans is the generic bioequivalent of Revatio, with the same active and strength for the PAH indication.<\/p>\n Pulmonary arterial hypertension is driven by pathological remodelling, vasoconstriction, and in-situ thrombosis of the small pulmonary arteries. The nitric oxide (NO) → cGMP pathway<\/strong> is impaired in PAH — endothelial NO production is reduced and cGMP turnover is elevated.<\/p>\n Sildenafil in PAH does NOT cure the disease<\/strong> — it is a symptomatic and haemodynamic treatment that slows progression and improves quality of life. Many patients progress on PDE5-inhibitor monotherapy and require add-on treatment with endothelin receptor antagonists and\/or prostanoids. The treatment plan is managed by the PAH specialist.<\/p>\n Although 80 mg three times daily has been studied in adult PAH, the additional benefit over 20 mg TID is minimal at best and side effects rise substantially. Current ESC\/ERS and CHEST PAH guidelines recommend 20 mg TID as the standard adult dose<\/strong>. Higher doses are reserved for specialist cases.<\/p>\n FDA-approved paediatric doses for PAH in children 1-17 years are 10 mg three times daily<\/strong> for body weight ≤ 20 kg, or 20 mg three times daily<\/strong> for body weight > 20 kg. However, the 2012 FDA Drug Safety Communication specifically cautioned against higher-than-recommended doses in children following the STARTS-2<\/em> trial mortality signal at 40 \/ 80 mg TID paediatric doses. Paediatric use should be confined to specialist paediatric PAH clinics<\/strong>.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
What Is Assurans 20 mg?<\/h2>\n
How Assurans Works in PAH<\/h2>\n
\n
When Assurans Is Used<\/h2>\n
FDA-approved \/ EMA-approved indications<\/h3>\n
\n
Off-label \/ specialist use<\/h3>\n
\n
Uses that are NOT appropriate<\/h3>\n
\n
Assurans Dose and How to Take<\/h2>\n
Standaard dosis voor volwassenen<\/h3>\n
\n
Higher doses and titration<\/h3>\n
Dose adjustment<\/h3>\n
\n
Paediatric dose (specialist use only)<\/h3>\n
Bijwerkingen<\/h2>\n
Common (>10%)<\/h3>\n
\n
Less common (1-10%)<\/h3>\n
\n
Zeldzaam maar ernstig \u2014 zoek onmiddellijk medische hulp<\/h3>\n
\n
Contra-indicaties & waarschuwingen<\/h2>\n
\n
Geneesmiddelinteracties<\/h2>\n